Solid Biosciences Inc. (SLDB)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q2 '18 Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -74.9M Q4 '21: -72.3M Q1 '22: -80.7M Q2 '22: -87.4M Q3 '22: -90.5M Q4 '22: -106.5M Q1 '23: -113.1M Q2 '23: -114.6M Q3 '23: -116.6M Q4 '23: -104.3M Q1 '24: -99.1M Q2 '24: -100M Q3 '24: -112.1M Q4 '24: -129.7M Q1 '25: -142.9M Q2 '25: -156.8M Q3 '25: -169.7M Q4 '25: -179.2M Q1 '26: -196.5M Q2 '26: -212.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-240M -160M -80M 0 80M 160M 240M Q3 '21: -74.9M Q4 '21: -72.2M Q1 '22: -80.6M Q2 '22: -87M Q3 '22: -89.4M Q4 '22: -86M Q1 '23: -90.7M Q2 '23: -90.3M Q3 '23: -90.8M Q4 '23: -96M Q1 '24: -90.2M Q2 '24: -90.7M Q3 '24: -102.4M Q4 '24: -124.7M Q1 '25: -139.7M Q2 '25: -154.1M Q3 '25: -167.1M Q4 '25: -174.3M Q1 '26: -191.8M Q2 '26: -207.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -55.6M Q4 '21: -77.8M Q1 '22: -83.6M Q2 '22: -82.4M Q3 '22: -84.4M Q4 '22: -98M Q1 '23: -98.8M Q2 '23: -110.4M Q3 '23: -107.8M Q4 '23: -94.2M Q1 '24: -91.4M Q2 '24: -85.4M Q3 '24: -91.2M Q4 '24: -100M Q1 '25: -106.7M Q2 '25: -122.6M Q3 '25: -132.4M Q4 '25: -156.3M Q1 '26: -171.7M Q2 '26: -186.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-210M -140M -70M 0 70M 140M 210M Q3 '21: -56.3M Q4 '21: -79M Q1 '22: -85M Q2 '22: -84.6M Q3 '22: -87.2M Q4 '22: -101M Q1 '23: -102.1M Q2 '23: -113.1M Q3 '23: -110.1M Q4 '23: -95.7M Q1 '24: -92.5M Q2 '24: -86.3M Q3 '24: -91.7M Q4 '24: -100.7M Q1 '25: -107.3M Q2 '25: -123.3M Q3 '25: -133.2M Q4 '25: -157.4M Q1 '26: -172.9M Q2 '26: -187.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '21: 112.3M Q3 '21: 7.5M Q1 '22: 7.5M Q2 '22: 7.5M Q3 '22: 7.5M Q1 '23: 19.6M Q2 '23: 19.7M Q3 '23: 20.1M Q1 '24: 38.2M Q2 '24: 40.9M Q3 '24: 41.4M Q1 '25: 66.3M Q2 '25: 94.1M Q3 '25: 94.4M Q1 '26: 109.8M Q2 '26: 143.7M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -3.07 Q4 '21: -5.22 Q1 '22: -8.40 Q2 '22: -11.56 Q3 '22: -11.87 Q4 '22: -10.09 Q1 '23: -8.26 Q2 '23: -6.18 Q3 '23: -4.52 Q4 '23: -4.84 Q1 '24: -3.94 Q2 '24: -3.30 Q3 '24: -3.04 Q4 '24: -3.06 Q1 '25: -3.01 Q2 '25: -2.82 Q3 '25: -2.51 Q4 '25: -2.02 Q1 '26: -1.95 Q2 '26: -1.91 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.